Filter results
08/11/2023
ROVI reports operating revenue growth of 3% for the first nine months of the first post-pandemic year
04/08/2023
For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world rating of ESG risks drawn up by Sustainalytics
28/07/2023
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults
26/07/2023
ROVI achieved stable total revenue of 381.0 million euros in the first post-pandemic half year
10/05/2023
ROVI reached 201.9 million euros of revenue in the first post-pandemic quarter
25/04/2023
ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE)
The objective of the new three-monthly formulation is to reach bioequivalence in the plasma levels of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg
12/04/2023
The objective is to help improve society’s mental health and take advantage of the opportunities the new technologies offer to enhance the quality of life and the care that people receive.
27/03/2023
The group is collaborating with ReTree to recover an area of the Sierra del Rincón through reforestation with native tree species
21/03/2023
ROVI joins BioSim to strengthen initiatives that promote greater access to and knowledge about biosimilar medicines.